期刊文献+

38例消化系统神经内分泌癌的临床诊疗分析 被引量:13

Clinicopathologic features, diagnosis and treatment of 38 neuroendocrine carcinoma in the digestive system
原文传递
导出
摘要 目的 探讨消化系统神经内分泌癌的临床病理特点及其诊疗.方法 回顾性分析1985年1月至2008年3月间收治的38例消化系神经内分泌癌的临床资料.结果 本组男29例,女9例.有黑便或便血21例(55%).腹痛19例(50%),腹部包块15例(39%),便秘14例(37%),直肠肿物12例(32%),腹胀11例(29%),大便次数增多或腹泻7例(18%).均采用手术治疗,其中1例行食管癌根治术,5例行根治性全胃切除.1例行姑息性近端胃切除术,2例行胃局部切除术,6例行胰十二指肠切除术,1例行胰体尾切除,3例行小肠部分切除术,7例行根治性右半结肠切除术,5例行经腹 直肠癌前切除术,3例行腹会阴联合直肠癌根治术,4例行直肠局部切除术.36例患者获得3~144个月的随访,中位随访时间70个月,1、3、5年生存率分别为94.7%、86.8%和57.9%,中位生存期为62个月.肿瘤浸润深度超过肌层组的生存期[(36±5)个月]明显短于肿瘤浸润深度未超过肌层组[(73±5)个月](P〈0.05).有淋巴结转移组的生存期[(34±7)个月]明显短于无淋巴结转移组[(74±5)个月](P〈0.05).结论 消化系统神经内分泌癌的临床表现无特异性,手术治疗是有效的方法. Objective To investigate the clinicopathologic features, diagnosis and treatment of neuroendocrine carcinoma(NEC)in the digestive system. Methods Thirty-eight patients with NEC from Jan 1985 to Mar 2008 were analyzed retrospectively and the related literatures were reviewed. Results There were 29 males and 9 females. Common symptoms were melena or hematochezia(n=21,55%),abdominal pain(n=19,50%),abdominal mass(n=15,39%),constipation(n=14,37%),rectal maas(n=12,32%),abdominal distention(n=11,29%)and diarrhea(n=7,18%).All the patients received surgical treatment including 1 esophagectomy,5 radical total gastrectomies,1 palliation proximal gastric resection,2 local gastric resections,6 pancreaticoduodenectomies,1 distal pancreatectomies,3 partial small intestine resections,7 radical right hemicolectomies,5 Dixon operations,3 Miles operations,and 4 local resections of rectal tumor. Thirty-six patients received follow-up.The follow-up time ranged from 3 months to 144 months(median,70months).The 1-,3-and 5-year survival rates were 94.7%,86.8%.and 57.9%respectively.The median survival time was 62 months.The survival time of the patients with carcinoma infiltration exceeding bowel muscularis propria was(36±5)months,significantly shorter than that of patients without carcinoma infiltration exceeding the bowel muscularis propfia[(73±5)monks,P〈0.05].The survival time of the patients with positive lymph node metastasis was(34±7)months,significantly shorter than that of patients with negative lymph node metastasis[(74±5)months,P〈0.05].Conclusions Clinical symptoms,signs of neuroendocrine carcinoma in the digestive system are nonspecific.The correct diagnosis should depend on histopathologic examination. Systematic treatments including radical resection of NEC are the preferable treatment.
出处 《中华胃肠外科杂志》 CAS 北大核心 2010年第8期587-589,共3页 Chinese Journal of Gastrointestinal Surgery
关键词 消化系统 神经内分泌癌 诊断 外科手术 Digestive system Neuroendocrine carcinoma Diagnosis Surgical procedures
  • 相关文献

参考文献1

二级参考文献16

  • 1G. Rindi,G. Kl?ppel,A. Couvelard,P. Komminoth,M. K?rner,J. M. Lopes,A.-M. McNicol,O. Nilsson,A. Perren,A. Scarpa,J.-Y. Scoazec,B. Wiedenmann.TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system[J].Virchows Archiv.2007(4)
  • 2Guido Rindi,Tiziana D’Adda,Elisabetta Froio,Giovanni Fellegara,Cesare Bordi.Prognostic Factors in Gastrointestinal Endocrine Tumors[J].Endocrine Pathology.2007(3)
  • 3J. P. Esser,E. P. Krenning,J. J. M. Teunissen,P. P. M. Kooij,A. L. H. Gameren,W. H. Bakker,D. J. Kwekkeboom.Comparison of [177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0,Tyr3]octreotide: which peptide is preferable for PRRT?[J].European Journal of Nuclear Medicine and Molecular Imaging.2006(11)
  • 4G. Rindi,G. Kl?ppel,H. Alhman,M. Caplin,A. Couvelard,W. W. Herder,B. Erikssson,A. Falchetti,M. Falconi,P. Komminoth,M. K?rner,J. M. Lopes,A-M. McNicol,O. Nilsson,A. Perren,A. Scarpa,J-Y. Scoazec,B. Wiedenmann.TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system[J].Virchows Archiv.2006(4)
  • 5D. J. Kwekkeboom,W. H. Bakker,B. L. Kam,J. J. M. Teunissen,P. P. M. Kooij,W. W. de Herder,R. A. Feelders,C. H. J. van Eijck,M. de Jong,A. Srinivasan,J. L. Erion,E. P. Krenning.Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate[J].European Journal of Nuclear Medicine and Molecular Imaging.2003(3)
  • 6David S. Tichansky M.D.,,Burt Cagir M.D.,,Edward Borrazzo M.D.,Allan Topham B.A.,Juan Palazzo M.D.,Eric J. Weaver M.D., Ph.D.,Andrea Lange M.D.,Robert D. Fry M.D.Risk of Second Cancers in Patients with Colorectal Carcinoids[J].Diseases of the Colon & Rectum.2002(1)
  • 7Yao JC,Hoff PM.Molecular targeted therapy for neuroendocrine tumors[].Hematology Oncology Clinics of North America.2007
  • 8Yao JC,Phan A,Hoff PM,Chen HX,Charnsangavej C,Yeung SC,Hess K,Ng C,Abbruzzese JL,Ajani JA.Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b[].Journal of Clinical Oncology.2008
  • 9Kwekkeboom DJ,de Herder WW,Kam BL,van Eijck CH,van Essen M,Kooij PP,Feelders RA,van Aken MO,Krenning EP.Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival[].Journal of Clinical Oncology.2008
  • 10Modlin IM,Oberg K,Chung DC,Jensen RT,de Herder WW,Thakker RV,Caplin M,Delle Fave G,Kaltsas GA,Krenning EP,Moss SF,Nilsson O,Rindi G,Salazar R,Ruszniewski P,Sundin A.Gastroenteropancreatic neuroendocrine tumours[].The Lancet Oncology.2008

共引文献44

同被引文献62

引证文献13

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部